Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces an exclusive digital and advanced
analytics collaboration with Healthcare Outcomes Performance
Company (HOPCo) – the world’s largest, fully-integrated,
musculoskeletal (MSK) value-based care and outcomes management
company. This collaboration will focus on enhancing solutions for
ASC customers, physicians, and their patients through HOPCo’s
digital health and analytics platforms,
myrecovery® and Vitals®
The partnership with HOPCo provides a comprehensive technology
platform that encompasses all musculoskeletal procedures performed
in the ASC segment. The AI-powered myrecovery
platform enhances the clinical experience by utilizing patient
engagement tools such as remote care management, real time
communications, and remote therapeutic monitoring (RTM), while
providing critical* quality outcome metrics through proprietary
activity tracking technology, functional outcomes reporting,
patient-reported outcomes (PROMs), and longitudinal data
integration across a patient’s care journey. HOPCo’s
Vitals platform provides tools, analytics, and
dashboards to help Smith+Nephew customers deliver better, more
efficient and coordinated care while also meeting value-based care
requirements aiming to reduce cost.
"We are thrilled to partner with HOPCo and the ability to bring
their innovative digital solutions to customers in the ASC across
both our Orthopaedic and Sports Medicine businesses. The HOPCo
solutions will allow our customers to unlock value in the ASC be it
through the use of RTM, PROMs, or leveraging analytics to drive
efficiencies. Their commitment to driving meaningful change in
outcomes through data aligns perfectly with the strength
and value of the CORI◊ Surgical System," said Craig Gaffin,
President of Global Orthopaedics at Smith+Nephew. "This
collaboration underscores our commitment to advancing orthopaedic
surgery through innovative technology, improving patient outcomes,
and transforming the future of healthcare."
Data from the CORI Surgical System’s ability to perform
image-agnostic robotic-assisted knee surgeries will now be
augmented with the powerful data-driven insights from HOPCo’s
Vitals and AI-powered myrecovery
digital solutions. The integrated digital platform will encompass
some of the most advanced practice and health system analytics
solutions available. Planned integration with Smith+Nephew’s
intraoperative data from the CORI Surgical System through
RI.INSIGHTS Data Visualization Platform will provide surgeons and
healthcare providers with enhanced analytics to link personalized
surgical planning, intra-operative decision-making, and PROMS
tracking and optimization.
“Smith+Nephew is clearly committed to using outcomes data to
enhance the value of its products and services,” said Dr. David
Jacofsky, CEO and Chairman at HOPCo. “HOPCo’s
myrecovery and Vitals platforms
will allow Smith+Nephew to leverage unique longitudinal data to do
just that, while simultaneously providing meaningful additional
value to customers and improving patient outcomes.”
- ends –
* https://www.federalregister.gov/documents/2023/11/22/2023-24293/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment
Media Enquiries Dave Snyder
+1 (978)
749-1440 Smith+Nephew
david.snyder@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
About HOPCo
Healthcare Outcomes Performance Company (HOPCo) is the global
leader of integrated musculoskeletal value-based health outcomes
management, digital analytics, practice management, and health
system service line management. This includes comprehensive
expertise across all MSK specialties, including orthopedics, spine,
pain management, rehabilitation, neurosurgery, and neurology.
HOPCo's integrated care, analytics, and facilities development
platforms have proven to increase the quality of patient care while
reliably reducing the total cost of MSK care across the care
continuum for practices, health systems and payors alike. HOPCo's
affiliated payors, practices and health systems successfully
participate in highly efficient value-based contracting (bundled
payments, population health programs, and other advanced risk-based
arrangements) utilizing HOPCo's proprietary platforms, IT
solutions, integrated analytics, advanced medical economics and
standardized care pathways. Visit www.hopco.com to learn
more.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Smith and Nephew (NYSE:SNN)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Smith and Nephew (NYSE:SNN)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
